The conflicting safety signal One real-world evidence study found that patients receiving GLP-1 receptor agonists had higher risks of certain autoimmune conditions, including ulcerative colitis, rheumatoid arthritis, autoimmune thyroiditis, ankylosing spondylitis, and psoriasis, compared to those on DPP-4 inhibitors
The numbers tell the story: 500,000+ patients served and $1.6 billion in first-year sales
YL: Conceptualization, Visualization, Writing review and editing
Because the majority of the -cells do not express GLP-1R, and also because GLP-1 inhibits glucagon secretion even in T1D patients with low insulin pancreatic reserve, the mechanism by which GLP-1 decreases glucagon secretion is still a matter of debate [15]
The studies on retatrutide so far have been relatively short, so were still learning about potential side effects
Gigliotti contrasts such a patient with a person who has a BMI of 40 and diagnoses of hypertension, type 2 diabetes, CVD, and musculoskeletal issues, who may benefit from lifelong use of weight management medications